NICE recommends against Opdivo for urothelial cancer

The U.K.'s NICE issued draft guidance recommending against the use of Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat advanced urothelial cancer in patients who have had platinum-co...